The Luketich laboratory at the Hillman Cancer was established in 1999 and is directed by James Luketich, MD, Chairman, Department of Cardiothoracic Surgery. The focus of the laboratory is the study of the molecular signatures of thoracic malignancies, with a particular focus on esophageal adenocarcinoma.
The goal is to provide physicians with new molecular analysis tools to improve the accuracy and timeliness of cancer diagnosis and staging, and to predict prognosis. The clinical relevance of findings to diagnosis and prognosis remains a central theme. The NIH funded the Luketich Laboratory beginning in 2001.